LESLIE MCCOLLUM: Open Payments
NPI 1710115506 · TUPELO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$630 in 24 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $543 · 2025 $630
Food & beverage: $630
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $178 |
| Madrigal Pharmaceuticals | 2 | $117 |
| Lilly USA, LLC | 3 | $62 |
| GENZYME CORPORATION | 2 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Sandoz Inc. | 1 | $24 |
| Gilead Sciences, Inc. | 1 | $22 |
| QOL Medical, LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
Products named: TREMFYA, REZDIFFRA, OMVOH, DUPIXENT, XIFAXAN, INJECTAFER, HYRIMOZ, Sucraid.
Industry payments across MS — which companies pay providers there.
